German patients get the latest drugs for just $11. Can such a model work in the U.S.?

The United States is currently facing a rise in the cost of specialty drugs, but the nation may be able to learn from Germany's successful approach to a drug pricing initiative. Based on keeping government involvement to a minimum, new drugs must go through a series of evaluations with a non-governmental agency before entering the market to prove that the new drug has an added benefit compared to the existing drug therapies.

Related Stories